Table of Contents: 1 Introduction 1.1.1 Prevalence of the Uterine Fibroids in U.S. 2 Scope of Study 2.1 Research Objective 2.2 Assumptions & Limitations 2.2.1 Assumptions 2.2.2 Limitations 2.3 Market Structure 3 Research Methodology 3.1 Primary Research 3.2 Secondary Research 4 U.S. Uterine Fibroid Market 4.1 Introduction 4.2 U.S. Uterine Fibroid Market, By Type 4.3 U.S. Uterine Fibroid Market, By Diagnosis 4.4 U.S. Uterine Fibroid Market, By Treatment 5 Company Profile 5.1 AstraZeneca 5.1.1 Company Overview 5.1.2 Product overview 5.1.3 Financial Overview 5.1.4 Key Development 5.1.5 SWOT Analysis 5.2 Cook Medical Inc. 5.2.1 Overview 5.2.2 Product Overview 5.2.3 Financials 5.2.4 Key Developments 5.2.5 SWOT Analysis 5.3 Boston Scientific Corporation 5.3.1 Company Overview 5.3.2 Product/Business Segment Overview 5.3.3 Financial Overview 5.3.4 Key Development 5.3.1 SWOT Analysis 5.4 GE Healthcare 5.4.1 Company Overview 5.4.2 Product/Business Segment Overview 5.4.3 Financial Overview 5.4.4 Key Development 5.4.5 SWOT Analysis 5.5 AbbVie Inc. 5.5.1 Company Overview 5.5.2 Product/Business Segment Overview 5.5.3 Financial Overview 5.5.4 Key Development 5.5.5 SWOT Analysis 5.6 Hologic, Inc. 5.6.1 Company Overview 5.6.2 Product/Business Segment Overview 5.6.3 Financial Overview 5.6.4 Key Development 5.6.5 SWOT Analysis

List of Tables: TABLE 1 U.S. UTERINE FIBROID MARKET, BY TYPE, 2013-2022 (USD MILLION) TABLE 2 U.S. UTERINE FIBROID MARKET, BY DIAGNOSIS, 2013-2022 (USD MILLION) TABLE 3 U.S. UTERINE FIBROID MARKET, BY TREATMENT, 2013-2022 (USD MILLION) TABLE 4 U.S. UTERINE FIBROID MARKET, BY TREATMENT TYPE, 2013-2022 (USD MILLION) TABLE 5 PIPELINE PRODUCTS FOR UTERINE FIBROIDS TABLE 6 ASTRAZENECA: KEY DEVELOPMENT TABLE 7 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENT TABLE 8 GE HEALTHCARE: KEY DEVELOPMENT TABLE 9 ABBVIE INC.: KEY DEVELOPMENT TABLE 10 HOLOGIC INC.: KEY DEVELOPMENT List of Figures: FIGURE 1 COMPARISON BETWEEN DIAGNOSIS & TREATMENT MARKET, 2013-2022 (USD MILLION) FIGURE 2 U.S. UTERINE FIBROID MARKET: MARKET STRUCTURE FIGURE 3 RESEARCH PROCESS FIGURE 4 U.S. UTERINE FIBROID MARKET, BY TYPE, 2015 & 2022 (USD MILLION) FIGURE 5 U.S. UTERINE FIBROID MARKET, BY DIAGNOSIS, 2015 & 2022 (USD MILLION) FIGURE 6 TREATMENTS FOR UTERINE FIBROIDS FIGURE 7 U.S. UTERINE FIBROID MARKET, BY TREATMENT, 2013-2022 (USD MILLION) FIGURE 8 U.S. UTERINE FIBROID MARKET, BY TREATMENT TYPE, 2015 & 2022 (USD MILLION) FIGURE 9 PHARMACOTHERAPY TREATMENT FORECAST, 2015-2022 FIGURE 10 ASTRAZENECA: RECENT FINANCIAL FIGURE 11 ASTRAZENECA: GEOGRAPHICAL MIX FIGURE 12 ASTRAZENECA: OPERATING SEGMENTS FIGURE 13 ASTRAZENECA: SWOT ANALYSIS FIGURE 14 BOSTON SCIENTIFIC CORPORATION: RECENT FINANCIAL FIGURE 15 BOSTON SCIENTIFIC CORPORATION: RECENT FINANCIAL FIGURE 16 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS FIGURE 17 GE HEALTHCARE: RECENT FINANCIAL FIGURE 18 GE HEALTHCARE: GEOGRAPHICAL MIX FIGURE 19 GE HEALTHCARE: OPERATING SEGMENTS FIGURE 20 GE HEALTHCARE: SWOT ANALYSIS FIGURE 21 ABBVIE INC.: RECENT FINANCIAL FIGURE 22 ABBVIE INC.: GEOGRAPHICAL MIX FIGURE 23 ABBVIE INC: OPERATING SEGMENTS FIGURE 24 ABBVIE INC.: SWOT ANALYSIS FIGURE 25 HOLOGIC INC.: RECENT FINANCIAL FIGURE 26 HOLOGIC INC: GEOGRAPHICAL MIX FIGURE 27 HOLOGIC INC: OPERATING SEGMENTS FIGURE 28 HOLOGIC INC.: SWOT ANALYSIS

AstraZeneca (England), Cook Medical Inc. (US), Boston Scientific Corporation (US), GE Healthcare (U.K.), AbbVie Inc. (U.S.), Hologic (U.S.), and others.